Local News

• Insecticide Movento(R) approved in United States and Canada  The new insecticidal active ingredient spirotetramat from Bayer CropScience has been granted regulatory approval in the strategically important markets in the United States and Canada. Spirotetramat will be marketed worldwide under the brand name Movento(R).
  Bayer July 03, 2008  
• OSI Pharmaceuticals announces conversion period for Convertible Notes  OSI Pharmaceuticals announced that its 2% Convertible Senior Notes due 2025 are now convertible at the option of the holders and will remain convertible through September 30, 2008, the last trading day of the current fiscal quarter, as provided for in the Indenture governing the notes.
  OSI Pharmaceuticals, Inc. July 03, 2008  
• Wyeth and Progenics receive approval from European Commission for RELISTOR  Wyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals announced that the companies have received marketing approval for RELISTOR(TM) (methylnaltrexone bromide) subcutaneous injection from the European Commission.
  Progenics Pharmaceuticals, Inc. July 03, 2008  
• Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen  Bayer HealthCare is expanding its commitment to hemophilia with the acquisition of Maxygen's hemophilia program assets, including a next-generation recombinant Factor VIIa protein known as MAXY-VII. The lead therapeutic candidate is expected to enter Phase 1 clinical testing in 3Q 2008.
  Bayer July 02, 2008  
• Thermo Fisher Scientific acquires Open Biosystems, creating unmatched RNAi platform  Thermo Fisher Scientific announced that it has acquired Open Biosystems, a provider of RNA interference (RNAi), gene expression and protein detection products for life science research and drug discovery and development. The acquisition expands the company's leadership position in the RNAi field.
  Thermo Fisher Scientific Inc. July 02, 2008  
• Cubist to promote in the U.S. AstraZeneca's broad spectrum antibiotic, MERREM I.V.  Cubist Pharmaceuticals announced that it has signed an exclusive agreement with AstraZeneca to promote and provide other support in the United States for MERREM(R) I.V. (meropenem for injection), an established broad spectrum (carbapenem class) I.V. antibiotic.
  Cubist Pharmaceuticals, Inc. July 02, 2008  
• Summary judgment granted for SEROQUEL patent litigation in the US  AstraZeneca announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries and Sandoz alleging infringement of AstraZeneca's patent.
  AstraZeneca July 02, 2008  
• Monsanto Company completes acquisition of Semillas Cristiani Burkard  Monsanto announced that it has completed its proposed acquisition of Marmot, which operates Semillas Cristiani Burkard (SCB), a privately-held seed company headquartered in Guatemala City, Guatemala. SCB is the leading Central American corn seed company focused on hybrid corn production.
  Monsanto Company July 02, 2008  
• Implant Sciences continues the divestiture of non-strategic assets  Implant Sciences Corporation announced the execution of a definitive agreement selling certain assets used in the production of coating medical products. The Company received gross cash proceeds of approximately $750,000 in connection with this sale.
  Implant Sciences Corporation July 02, 2008  
• GTC Biotherapeutics receives notice related to NASDAQ minimum market value rule  GTC Biotherapeutics has received a letter from The Nasdaq Stock Market notifying GTC that for the last 10 consecutive trading days the aggregate market value of GTCB common stock has fallen below $50 million, the minimum level required for continued listing on the Nasdaq Global Market.
  GTC Biotherapeutics, Inc. July 02, 2008  

   (next 10 articles)